Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates
17 Pág.
Saved in:
Main Authors: | , , , , , , , , , , |
---|---|
Other Authors: | |
Format: | artículo biblioteca |
Language: | English |
Published: |
Frontiers Media
2023-12-12
|
Subjects: | COVID-19, MVA-based vaccine, S protein, SARS-CoV-2, Efficacy, Immunogenicity, Mice, Variants of concern, |
Online Access: | http://hdl.handle.net/10261/349371 http://dx.doi.org/10.13039/501100003339 http://dx.doi.org/10.13039/501100004837 http://dx.doi.org/10.13039/501100004587 http://dx.doi.org/10.13039/501100000780 http://dx.doi.org/10.13039/501100011033 https://api.elsevier.com/content/abstract/scopus_id/85180695762 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | 17 Pág. |
---|